Skip to main content
. 2020 Oct 27;8(2):e001238. doi: 10.1136/jitc-2020-001238

Figure 4.

Figure 4

N-820 significantly enhanced granzyme B and IFN-γ release from exPBNK cells against rituximab-sensitive and rituximab-resistant BL cells. The purified exPBNK cells were co-cultured with Raji, Raji-2R, or Raji-4RH in combination with 10 nM IgG, 10 nM N-803, 10 nM N-820, 10 nM rituximab, 10 nM N-803+10 nM rituximab, or 10 nM obinutuzumab for 3 days. The supernatants from the culture were used for ELISA. Supernatants from Raji, Raji-2R, or Raji-4RH without exPBNK cells were used as controls. N-820 significantly enhanced granzyme B release from exPBNK cells as compared with other agents (A). N-820 significantly enhanced IFN-γ release from exPBNK cells as compared with other agents (n=4) (B). *p<0.05, **p<0.01, ***p<0.001, ns=not significant, Ritux=Rituximab, Obinu=Obinutuzumab.